Estudio de Efectividad del ENALAPRIL Comparado con Losartán, en la Conservación de la función Renal Residual en Pacientes en Diálisis Peritoneal Automatizada

Abstract

Background. Residual renal function (RRF) is an important determinant of mortality and morbidity in patients receiving peritoneal dialysis (PD). Recent studies have shown a positive effect of angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) on RRF in automated peritoneal dialysis patients (APD). Objective. Comparison between enalapril and losartan for RRF preservation in APD patients. Material and methods. An open label randomized controlled trial (RCT) with a 12 month follow-up period was conducted to compare the effect of enalapril versus losartan on RRF preservation in 60 APD patients. Measurements were done at the start of the study (baseline), 3, 6, 9, and 12 months. Results. RRF in the enalapril group dropped from 3.65+1.6 (baseline) to 2.36+0.38 ml/min/l.73m2 (12 months). In the losartan group RRF was reduced from 4.1+2.01 (baseline) to 2.54+0.47 ml/min/l.73m2 (12 months). There were not significant differences between the two groups regarding RRF at 12 months. Conclusions. There was not significant difference on RRF preservation between enalapril and losartan groups. The treatment with any of the drugs is useful in preserving RRF.